Immupharma (IMM)

 

Latest News

ImmuPharma completes dosing in Lupuzor study

ImmuPharma has confirmed that the last patient has completed dosing within the 52-week, randomised, double-blinded, p...

Grant of Options

RNS Number: 0005A Immupharma PLC 21 December 2017 21 DECEMBER 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Grant of Options ImmuPharma PLC (LSE:IMM) , ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 900,000 ordinary s...

Last patient completes dosing in LupuzorT Trial

RNS Number: 0003A Immupharma PLC 21 December 2017 21 DECEMBER 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Last patient completes dosing in Lupuzor Pivotal Phase III Study ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm that the last patient has completed dosing within the...

Broker Forecast - finnCap issues a broker note on ImmuPharma PLC

finnCap today initiates coverage of ImmuPharma PLC (LON:IMM) with a buy investment rating and price target of 237p...

All News

DateHeadlineSource
27-09-17ImmuPharma revenues riseStockMarketWire
27-09-17Interim ResultsRNS
26-09-17Preparation of Lupuzor'sT Regulatory SubmissionsRNS
21-09-17Update on LupuzorT Pivotal Phase III StudyRNS
19-09-17ImmuPharma schedules interims StockMarketWire
19-09-17Notification of Interim ResultsRNS
18-08-17AIM Rule 17 NoticeRNS
12-07-17Grant of OptionsRNS
30-06-17Result of AGMRNS
30-06-17Broker Forecast - Northland Capital issues a broker note on ImmuPharma PLCStockMarketWire
30-06-17Update on LupuzorT Pivotal Phase III StudyRNS
07-06-17Annual Report & Notice of AGMRNS
01-06-17ImmuPharma losses widenStockMarketWire
01-06-17Final ResultsRNS
22-05-17Notification of Full Year ResultsRNS
17-05-17Lupuzor study on track, says ImmuPharma StockMarketWire
17-05-17Update on Lupuzor Phase III StudyRNS
31-03-17New Employee Share Option Plan & Grant of OptionsRNS
31-03-17New Employee Share Option Plan & Grant of OptionsRNS
24-03-17ImmuPharma to present at Master Investor ShowRNS
22-03-17Holding(s) in CompanyRNS
20-03-17Holding(s) in CompanyRNS
20-03-17Holding(s) in CompanyRNS
10-03-17?4.1 Million Fund Raise via Accelerated BookbuildRNS
10-03-17Accelerated Bookbuild for the Issue of EquityRNS
06-03-17Holding(s) in CompanyRNS
17-02-17Holding(s) in CompanyRNS
25-01-17Update on Lupuzor Phase III StudyRNS
24-01-17Change of AdviserRNS
29-12-16Holding(s) in CompanyRNS
22-12-16ImmuPharma completes Lupuzor patient recruitment StockMarketWire
22-12-16Update on Lupuzor Pivotal Phase III StudyRNS
16-11-16ImmuPharma update on cancer compound StockMarketWire
16-11-16Update on Cancer Compound IPP-204106 'Nucant'RNS
09-11-16Holding(s) in CompanyRNS
26-10-16Holding(s) in CompanyRNS
24-10-16ImmuPharma fundraising StockMarketWire
21-10-16Close of Accelerated BookbuildRNS
21-10-16ImmuPharma placing StockMarketWire
21-10-16Proposed Accelerated Bookbuild for Vendor PlacingRNS

RSS feeds

  • Editorial news feed for LSE:IMM Editorial
  • Regulatory news feed for LSE:IMM Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account